We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Novo Nordisk

Working together since 2013

Novo Nordisk logo 250pxw

Kymab granted Novo Nordisk a non-exclusive licence to our proprietary human antibody IntelliSelect™ Transgenic platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to specific IntelliSelect™ resources that can generate highly selective, potent, human antibody drug candidates.

Visit the Novo Nordisk website

Our unique platforms can deliver the finest novel therapeutic antibodies

Learn more